PC6, HT5 |
Delay the process of plaque instability, reduce the incidence of malignant cardiovascular events |
Reduce the serum content of matrix metalloproteinase-9(MMP-9) |
[15] |
PC6, HT5 |
Stabilize atherosclerotic plaque |
Decrease volume and the equivalent block of coronary artery calcified plaque (CACP) |
[23] |
PC6 |
Vasodilatation, lowering blood pressure, inhibiting platelet adhesion and aggregation, maintaining normal cardiac output, controlling collateral circulation opening, adjusting tissue perfusion, and protecting myocardial perfusion |
Decrease endothelin (ET) and increase nitric oxide (NO) |
[16] |
PC6, HT5 |
Improve the tension of the cardiac autonomic nervous system |
Increase heart rate variability (HRV) |
[24] |
PC6 |
Improve the prognosis of CSAP |
Decrease neutrophil-lymphocyte ratio (NLR) |
[25] |
PC6, RN17, HT6, SP10, LR3 |
Reduce inflammatory response |
Reduce the content of C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) |
[14] |